A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

被引：0
|
作者：
Gort, Eelke
Johnson, Melissa Lynne
Hwang, Jimmy J.
Pant, Shubham
Dunzinger, Ulrich
Riemann, Kathrin
Kitzing, Thomas
Janne, Pasi A.
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Biberach, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3651
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
    Johnson, M. L.
    Gort, E.
    Pant, S.
    Lolkema, M. P.
    Sebastian, M.
    Scheffler, M.
    Hwang, J.
    Duenzinger, U.
    Riemann, K.
    Kitzing, T.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S591 - S592
  • [2] Phase I dose-escalation trial of BI 1701963 with or without BI 3011441 in patients with KRAS-mutated solid tumors
    Chia, Lin C.
    CANCER SCIENCE, 2022, 113 : 953 - 953
  • [3] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [6] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [7] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [8] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
  • [9] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
12345